Abstract B021: tRNA fragments extracted from patient plasma extra cellular vesicles display potential as biomarkers for high-grade glioma

Résumé fourni par la source

Abstract Transfer RNA (tRNA) are non-coding RNAs that bring amino acids to ribosomes during translation. Recent studies have shown that cleaved fragments derived from tRNA (tRFs) serve regulatory roles in epigenetics, signaling, transcription, and translation. tRFs can be released from cells and can be found in extracellular vesicles to perform some aspects of paracrine signaling. Utilizing high throughput small RNA sequencing, we have identified over 750 uniquely or multi-mapped (6.9% of total sRNA mapped reads) tRFs in extracellular vesicles of high-grade glioma (IDH-WT) patient plasma. By performing differential expression analysis, we identified 6 upregulated tRFs and 36 downregulated tRFs between high-grade glioma plasma EVs and non-cancer controls (n = 14, FDR<0.05). Differentially expressed tRFs (all 42) were further analyzed using bioinformatic techniques (RNAhybrid and IntaRNA) to predict potential gene targets. By performing gene ontology analysis (ShinyGO) we found that 70 of 75 genes related to glioma formation were identified as potential gene targets, indicating a possible role of tRFs in the regulation and formation of gliomas. A number of differentially expressed tRFs were predicted to target cancer-related genes including Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT-1). This analysis demonstrates that tRFs may serve as important biomarkers and regulators with therapeutic potential in the future Citation Format: Thomson R Phinney, Ali Alwadei, Gabriel Gabriel Wajnberg, Jae Han, Simi Chacko, Kathleen Attwood, Jeremy Roy, Adriennne Weeks. tRNA fragments extracted from patient plasma extra cellular vesicles display potential as biomarkers for high-grade glioma [abstract]. In: Proceedings of the AACR Special Conference: Liquid Biopsy: From Discovery to Clinical Implementation; 2024 Nov 13-16; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(21_Suppl):Abstract nr B021.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.